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Just as biomarkers specific for diseases, biomarkers indicative of healthy conditions are valuable
for the early diagnosis,monitoring, and prognosis of diseases. Our study focused on discovering
via proteomics a stable panel of urinary proteins in the human healthy population. Urine sam-
ples were collected three times during 4 months from 100 male and 100 female healthy donors
and analyzed through four different fractionation techniques (i.e. in-gel, 2D-LC, OFFGEL, and
mRP) coupled with HPLC-Chip-MS/MS. Thus, 1641 urinary proteins were identified with a
high confidence, among which 70 exhibiting an intergender/day variation<0.25 were selected
and matched with the previously published five largest urinary proteomes to get 56 candidate
proteins. Next, a panel comprising 18 intact urinary proteins was constructed by comparing the
urinary proteomes via SDS-PAGE and 2DE. Finally, such 18 urinary proteins were validated via
enzyme-linked immunosorbent assay in eight healthy individuals. Most of these proteins had
been related to multiple rather than to single diseases. Therefore, we surmise that this protein
set could be used as a biomarker to assess the human health status. Further determinations of
the normal fluctuations of the single urinary proteins in this series using samples from large
numbers of healthy individuals are required prior to any application in clinical settings.
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1 Introduction
Human urine is one of the ideal sources for clinical diag-
nosis, especially for urinary system diseases, as urine can
be obtained noninvasively, in large quantities, and repeat-
edly. Urinary proteins might therefore be an ideal source of
biomarkers for several diseases [1]. Asmost illnesses are com-
plex and heterogeneous processes, it would be preferable to
use a constellation of individually informative proteins rather
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than a single one to assess the diseased condition. By means
of comparative proteomics, a lot of urinary proteins have
been reported as potential biomarkers for bladder cancer
[2], renal cell carcinoma [3], rejection of kidney transplants
[4, 5], acute kidney injury [6, 7], Fanconi syndrome [8], re-
nal failure in diabetic nephropathy [9], and others. However,
most biomarker candidates are likely to be related to multiple
diseases rather than to a single one. It should be reasonable
to assume that such proteins reflect human healthy condi-
tions, and that their changes in expression may indicate that
the people involved are affected by an unhealthy condition.
Therefore, establishing a secure panel of urinary proteins re-
flecting human healthy conditions would not only provide a
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reference set for identifying disease biomarkers, but also be
valuable for the early diagnosis, monitoring, and prognosis of
diseases. Our present study is focused on discovering urinary
biomarkers indicative of human healthy conditions through
proteomic approaches.
Even though many intensive studies on the normal uri-
nary proteome have been performed [10–14], a steady panel
of urinary proteins in the healthy human population has not
yet been established due to the considerable degree of dy-
namic variation proper of the urinary proteome [14–17]. It is
well known that urinary proteomes differ among individuals,
particularly between men and women. In addition to these
interindividual differences, the urinary proteome of the same
person varies at different times due to the effects of exercise,
diet, lifestyle, and other factors [14–17]. Here, to determine a
steady panel of urinary proteins in the human healthy popula-
tion,wefirst controlled on a large scale the individual dynamic
variations by collecting the urine samples from 200 healthy
donors aged 18–22 years. Next, the urinary proteins with the
dynamic intergender/day variations <0.25 were selected and
matched with the previously published five largest urinary
proteomes; thus, a reproducible set comprising 18 intact uri-
nary proteins was obtained via comparisons with the urinary
proteomes based on SDS-PAGE and 2DE [18,19]. Finally, the
18 urinary proteins were validated by ELISA in eight healthy
individuals. Most proteins in this set were shown to be linked
to multiple rather than single diseases. Therefore, it seems
reasonable to assume that this protein set would constitute a
reference marker revealing the human health status.
2 Materials and methods
2.1 Preparation of urinary proteins from healthy
people
The protocol for collecting urine samples was approved by
the Ethics Committee of the Southwest Hospital, Chongqing.
The samples were collected thrice, at zero time and after 2
and 4months, from 100 healthy male and 100 healthy female
Chinese volunteers with an age range of 18–22 years, who
underwent medical checkups and urine routine tests at the
Southwest Hospital. Clinical details on the study participants
are reported in Supporting Information Table S1. Each time,
all 100 male and 100 female urine samples were collected
on the same day and 10-mL urine was immediately taken
from each sample to build the male and female pools, respec-
tively. The pooled samples were centrifuged at 10 000 × g for
30 min at 4C to remove any cellular debris. The supernatant
was concentrated and desalted via tangential filtration in a
Lab-scale TFF system (Millipore, Billerica, MA, USA) using
a membrane with a cutoff of 10 kDa, and the volumes were
reduced to about 30 mL. The protein amount in the urine
concentrates was measured by Coomassie Protein Assay Kit
(Pierce, Rockford, IL, USA). The targeted high-abundance
proteins (i.e. albumin, IgG, antitrypsin, IgA, transferrin, and
haptoglobin) in the concentrated samples were depleted by
using an immune-affinity column. The amount of urinary
protein after depletion of high-abundance proteins was then
assessed as mentioned above. Soon after, the urine concen-
trates were stored at −80C.
2.2 1D SDS-PAGE and in-gel digestion
After depletion of the high-abundance proteins, the urinary
protein mixture (200 g) was loaded on a 10% Bis-Tris gel
(Novex; Invitrogen, Carlsbad, CA, USA) in accordance to the
manufacturer’s instructions. The gel lane was then cut into
18 pieces and performed in-gel tryptic digestion. After DTT
reduction and iodoacetamide alkylation, the proteins were
digested by trypsin (Promega, Madison, WI, USA) at 37C
overnight. Then, we used a solution of 30% ACN, 0.3% TFA,
and 100% ACN to extract the tryptic peptides. After organic
solvents were removed by using a vacuum centrifuge, the
extracts were reconstituted in 0.1% TFA for HPLC-MS/MS
analysis.
2.3 Reverse phase HPLC and in-solution digestion
The high-abundance protein depleted urinary protein
(200 g) was dissolved in 6 mol/L urea and 1.0% acetic acid.
The urinary protein mixture was separated on an mRP-C18
High-Recovery protein column (Agilent Technologies, Palo
Alto, CA, USA) at 80C with a linear multisegment gradient
as previously described by Jun Adachi and coworkers [10],
and a total of 22 fractions were collected. Each fraction was
dried in a vacuum centrifuge and performed in-solution tryp-
tic digestion as previously described by Foster and coworkers
[20]. Finally, the resulting peptide mixtures were desalted us-
ing reverse phase C18 StageTips and diluted in 0.1% TFA for
HPLC-MS/MS analysis.
2.4 OFFGEL electrophoresis
OFFGEL electrophoresis was performed as previously de-
scribed by Patric Ho¨rth and coworkers [21]. Briefly, the 3100
OFFGEL Fractionator and the OFFGEL Kit 3–10 (Agilent)
were applied following the user protocol. A total of 600 g
of the urinary protein tryptic digest was resuspended with
focusing buffer to a final volume of 3.6 mL. A total of 150 L
of this sample was loaded in each of the 24 wells. The sample
was focused using the recommended method for OFFGEL
peptides 24 wells fractionation with a maximum current of
50A and until 50 kVhwas reached. Corresponding peptides
fractions were pooled and concentrated by vacuum centrifu-
gation prior to HPLC-MS/MS analysis.
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2.5 On-line 2D-LC-ESI-MS/MS analysis
A total of 200 g high-abundance protein depleted uri-
nary protein mixtures were digested in-solution as described
above. After desalted by reverse phase C18 StageTips, the pro-
tein digest (10 L) was injected to a strong cation exchange
(SCX) column (300 m i.d. × 5 cm; Agilent Technologies,
Waldbronn, Germany) and eluted with ten salt plug injec-
tions (5–500 mM NaCl). Eleven fractions obtained from ten
salt plug injections were then introduced into the HPLC-
Chip/XCT Ultra Trap. The first four fractions were sepa-
rated with 2-h long gradients (2% B to 40% B in 110 min
and 40% B to 95% B in 10 min; where solvent A is
2% ACN, 0.1% formic acid, and solvent B is 0.1% formic
acid, 90% ACN) and the remaining fractions with 1-h long
gradient.
2.6 HPLC-Chip/MS analysis
The tryptic digested and desalted protein samples were ana-
lyzed with a HPLC-Chip-MS/MS system consisting of a nano
pump (G2226 A, Agilent) with four-channel microvacuum
degasser (G1379B, Agilent), a microfluidic HPLC-Chip Cube
interfaced to a XCT Ultra ion trap mass spectrometer (all
Agilent Technologies). Peptides were injected on the enrich-
ment column via an autosampler. The mobile phase con-
sisted of solvents A (water with 0.1% formic acid) and B
(90% ACN, 10% water with 0.1% formic acid). The column
was eluted with a gradient from 3% B to 45% B in 90 min,
followed by a steep gradient to 80% B in 10 min. The total
analysis time was 110 min, and the flow rate was fixed at
0.3 L/min.
Data-dependent MS acquisition was performed on the Ag-
ilent LC/MSD Trap XCT with the following MS conditions:
4 L/min, 300C; skim1: 30V; capillary exit: 75V; capillary volt-
age: 1800 V; for each precursor ion two averages were taken;
ion current control: on; trap drive: 85; smart target: 500 000;
MS scan range: 400–1600; maximum accumulation time:
150 ms; ultra scan: on. averages: 1; fragmentation ampli-
tude: 1.25 V; MS/MS: number of parents: 5; SmartFrag: on,
30–200%; spectra were actively excluded for fragmentation
after two recorded spectra for 1 min to allow the detection of
less abundant coeluting compounds; exclude+1: on,MS/MS
scan range: 100–2000; prefer +2: on; ion current control tar-
get: 500 000; ultra scan: on.
2.7 Database search
Database searches were performed against the IPI human
database (http://www.ebi.ac.uk/IPI) with the Spectrum Mill
Proteomics Workbench Rev A.03.03.078 software (Agilent
Technologies). The Spectrum Mill Data Extractor program
was used to create peak lists under the following conditions:
scans with the same precursor±1.4 m/z were merged within
a time frame of ±15 s. Charges up to a maximum of five
were assigned to the precursor ion. Precursor ions needed
with a minimum signal-to-noise value of 25. The 12C peak
was determined by the Data Extractor. Two missed cleavages
were allowed. Peptides were automatically identified by the
Spectrum Mill software using IPI human database (version
3.43) for tryptic peptides with the restriction to Homo sapi-
ens. A mass tolerance of ±2.5 Da for the precursor ions and a
tolerance of±0.7 Da for the fragment ions were used. A Spec-
trumMill autovalidation was run in protein details mode and
the peptide mode. Minimum scores, forward minus reversed
score threshold, minimum scored peak intensity, and rank
1 minus rank 2 score threshold for peptides were dependent
on the assigned precursor charge (Supporting Information
Table S2).
2.8 Enrichment analysis of Gene Ontology (GO)
categories
TheBiNGOpluginwas used to perform an enrichment analy-
sis of our urinary proteome dataset. For enrichment analysis,
our identified urinary proteome was used as a test dataset
and GO annotation for the complete human proteome as a
reference set. The analysis was performed with the “hyper
geometric test.” After correcting for multiple term testing by
Benjamini and Hochberg false discovery rate corrections, the
GO terms with p < 0.001 were selected as overrepresented
or underrepresented. Then, we used ClueGO, an easy way
to use the Cytoscape plug-in, to compare our results with
Max-Planck Unified (MAPU) urinary proteome GO terms.
2.9 Validation by ELISA
The urine samples were collected for validation from eight
healthy donors at five time points within 2 months. The clini-
cal details of these eight individuals are shown in Supporting
Information Table S4. After centrifuging the urine samples
at 10 000 × g for 30 min at 4C to remove cellular debris, the
supernatant was concentrated and desalted by using a mem-
branewith a cutoff of 10 kDa. The protein amount in the urine
concentrates wasmeasured using a Coomassie Protein Assay
Kit (Pierce). COL6A1,GC,RBP4,DNASE1,GAA, SERPING1,
CTSD, KNG1,UMOD, PIGR, AHSG, A1BG, AMBP, AZGP1,
PTGDS, HPX, CD14, and ORM1 proteins were quantified
with ELISA kits from Life Science Inc. according the manu-
facturer’s instructions.
2.10 Statistical analysis
The total number of identifiedMS/MS spectra for any protein
was used as the measurement of protein abundance in each
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sample. Protein abundance variation was defined as the ratio
of spectrum number standard variation and mean value of
a given protein among different samples [17]. Percentages
of variances were calculated from the median coefficient of
variation (CV), which is the standard deviation divided by the
mean of a measurement.
3 Results
The experimental strategy is outlined in Fig. 1. Briefly,
the urine samples from 100 male and 100 female healthy
donors were pooled together and next concentrated using a
10 kDa cut-off ultrafiltration membrane. The targeted high-
abundance proteins in the concentrated urine samples were
depleted by means of an immune-affinity column. Next, the
processed urinary protein samples were analyzed via four
different separation methods (SDS-PAGE (Supporting Infor-
mation Fig. S1A), mRP (Supporting Information Fig. S1B),
OFFGEL, and 2D-LC) coupled with the HPLC-Chip-MS/MS.
Tandem mass spectroscopic data were analyzed using the
SpectrumMill software and the IPI database restricted to hu-
mans using autovalidation criteria as described above (Sup-
porting Information Table S2).
Figure 1. An overview of the procedures used to analyze the
human urinary proteomes. HPLC, high-performance liquid chro-
matography; pI, isoelectric point; MW, molecular weight; LC, liq-
uid chromatography; RP, reversed phase;MS,mass spectrometry;
1-D SDS, one-dimensional sodium dodecyl sulfate; MARs, Multi-
ple Affinity Removal System; SCX, strong cation exchange. See
the text for details.
3.1 Whole urinary proteome of a human healthy
population
3.1.1 Identification of the urine proteome of a
human healthy population
A total of 103 901 spectra (5.7%) were ultimately selected
and interpreted as validated MS/MS spectra among the to-
tal spectra (1 832 582) produced from 456 raw files by the
mass spectrometer. Of the 103 901 validated MS/MS spectra,
23 201, 12 733, 44 732, and 23 235 MS/MS spectra were de-
rived from the datasets of SDS-PAGE, 2D-LC, OFFGEL, and
mRP, respectively (Supporting Information Table S3). In to-
tal, we identified 13 191 unique peptides, which mapped to
1641 nonredundant proteins (Supporting Information Data
S1), in which 1212 (73.9%) proteins were identified by at least
two unique peptides. Among all the identified peptides, 4485,
2537, 6065, and 3469 unique peptides, which represent 688,
540, 855, and 580 proteins, were derived from the datasets of
SDS-PAGE, 2D-LC, OFFGEL, and mRP (Supporting Infor-
mation Data S1), respectively (Table 1).
3.1.2 Summary of female and male urinary
proteomes
We compared the overall features of the urinary proteins
between male and female datasets (Supporting Information
Data S1). As shown in Fig. 2, there were 8031 peptides and
1125 proteins, 8257 peptides, and 1135 proteins in themale or
female datasets, respectively. Of those, 3099 (23.5%) peptides
and 619 (37.7%) proteins were found in both datasets. More-
over, there was no significant difference between male and
female datasets in distribution of molecular mass, isoelectric
point (pI), and predicted cellular localizations (Supporting
Information Fig. S2).
3.1.3 Urinary proteomes from four different
separations
Among the 13 191 identified peptides, 225 (1.7%) were found
in all four datasets, 632 (4.8%) in three of the four datasets,
1542 (11.7%) in two of the four datasets, and the remaining
10 792 (81.8%) in only one of the four datasets (Fig. 3A).
Of the 1641 identified proteins, 119 (7.3%) were found in all
four datasets, 218 (13.3%) in three of the four datasets, 229
(13.9%) in two of the four datasets, and the remaining 1075
(65.5%) in only one of the four datasets (Fig. 3B).
3.1.4 Comparison with the MAPU urinary proteome
So far, MAPU, one of the largest datasets, is derived from
the work of Adachi et al. [10,22]. They integrated five datasets
from gel or gel-free methods and reported 1543 proteins in
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Table 1. Experimental conditions and statistics on database searches constructed by means of four different separation methods
1D SDS-PAGE Reverse phase HPLC pI-based peptide 2D-LC
separation
Urinary protein 200 g 200 g 600 g 200 g
Albumin removal + + + +
Protein separation 12% Bis-Tris 1D gel mRP-C18 column − −
Peptide separation − − OFFGEL 3100 SCX + RP 2-DLC
Number of fraction 18 22 24 12
Digestion In-gel In-solution In-solution In-solution
Denaturant − 6 mol/L urea + 2 mol/L thiourea
Identified IT-MS2 spectra 29 576 24 380 45 617 13 133
Number of unique peptides 4485 3469 6065 2537
Number of identified proteins 688 580 855 540
Total number of unique peptides 13 191
Total number of identified proteins 1641
Figure 2. Comparison of the proteins identified in male and fe-
male urine pools. (A) Shared and not shared peptides. Numbers
represent the several different peptides in the respective over-
lapping and not overlapping areas; (B) shared and not shared
proteins. Numbers represent the various distinct proteins in the
respective overlapping and not overlapping areas.
urine. The overlapping of the urinary peptides and proteins
identified in MAPU and in our urinary proteome database
is shown in Fig. 4. A total of 3530 (27.8%) peptides and 804
(52.1%) proteins were present in both datasets. Following
GO analysis, a similarly functional category was shared be-
tweenMAPUsandoururinary proteomedataset. Thedetailed
GO analysis results are reported in Supporting Information
Figure 3. Comparison of the identified urinary proteins bymeans
of 2D-LC, OFFGEL, mRP, and 1D SDS-PAGE. (A) Shared and not
shared peptides. Numbers represent the various distinct pep-
tides in the respective overlapping and not overlapping areas.
(B) Shared and not shared. Numbers represent the several differ-
ent proteins in the respective overlapping and not overlapping
areas.
Fig. S3 and Data S2. We analyzed the protein GO clusters
of MAPUs and our urinary proteome database with ClueGO.
The results showed that about 95% common terms cluster
and about 5% specific terms cluster (Fig. 5).
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Figure 4. Relationship between the MAPU urinary proteome
database and our urinary proteome database. Numbers of
shared peptides or proteins are shown for our urinary proteome
database (in black), and the MAPU urinary proteome database (in
grey). (A) Numbers of shared peptides in the respective overlap-
ping and not overlapping areas. (B) Numbers of shared proteins
in the respective overlapping and not overlapping areas.
3.2 A stable set of urinary proteins in a healthy
human population
3.2.1 Control of urinary proteome variations related
to different individuals and ages
We collected morning urine samples from a total of 200 per-
sons thrice over 4 months (at 0, 2, and 4 months). These 100
males and 100 females were healthy with normally function-
ing kidney and their ages ranged between 18 and 22 years.
Each time, immediately after urine collection, we pooled the
100 males’ and 100 females’ urine samples, respectively.
Pooling the samples increased the abundance of common
proteins while decreasing that of individual-specific urinary
proteins; thus, the interindividual variations are significantly
reduced.
3.2.2 Control of urinary proteome variations related
to different genders and times
The abundance-evaluation approach applied in this study is
semiquantitative, and it can only be applied to proteins of a
relatively high abundance. The criterion of high-abundance
protein was arbitrarily set as unique peptides of>4 numbers
and spectra >10 numbers in each dataset. In the OFFGEL
group, a total of 101 (Supporting Information Data S3) and
127 (Supporting Information Data S4) common abundant
proteins with a median abundance variation 0.128 and 0.105
were selected in themale and female subgroups, respectively.
Further intergender variation analysis showed that 89 gender-
common abundant proteins had a median abundance varia-
tion of 0.229 (Supporting Information Data S5). In the mRP
group, 78 (Supporting InformationData S6) and 54 (Support-
ing Information Data S7) common abundant proteins with
median abundance variations of 0.102 and0.112were selected
in the male and female subgroups, respectively. Further in-
tergender variation analysis showed that 37 gender-common
abundant proteins had amedian abundance variation of 0.269
(Supporting Information Data S8). After removing the uri-
nary proteins with more than 0.25 interday or intergender
variation, a total of 70 proteins could be selected as potential
common abundant proteins in a healthy population. Among
these 70 proteins, 57 proteins were present in the OFFGEL
dataset and 21 proteins in the mRP dataset (Supporting In-
formation Data S9).
3.2.3. Validation of the common urinary proteome in
a healthy population
To prove that the 70 candidate proteins are indeed common
urinary proteins in a healthy population, we compared these
proteins with the previously published five largest urine pro-
teomes [10–14]. Among the 70 candidate proteins, 70 (100%)
were found in four datasets [10–14], and 66 (94.3%) were
present in all five datasets, excepting the CADM4, KLK1,
CD27, and UBC proteins. Furthermore, we compared these
66 proteins with the core urinary proteome reported by Na-
garjuna et al. [14]. Thus, a total of 56 proteins obtained as
common abundant urinary proteins in a healthy population
(Table 2).
3.3 Validation of intact proteins
Since urinary protein fragments and polypeptides might be
mistakenly taken as intact proteins, we reduced the possibil-
ity of such an erroneous identification concerning the 56 pro-
teins by comparing in-gel urinary proteome datasets. The cri-
terion of high-abundance proteinwas arbitrarily set as unique
peptides of>4 numbers and spectra of>30 numbers. A total
of 38 abundant proteins were found in the gel bands corre-
sponding to the Mr’s of the intact forms (Supporting Infor-
mation Data S10). These 38 proteins were also found in the
SDS-PAGE dataset reported by Adachi et al. [10]. To further
confirm these intact proteins, we compared the 38 proteins
with a urinary proteome based on 2DE gels obtained by com-
bining the urinary proteome datasets of Jisun Oh et al. [18]
and Rember Pieper et al. [19]. A total of 18 common urinary
intact proteins and three protein fragments (i.e. ITIH4, CP,
and HSPG2) appeared as distinct spots in 2DE gels [18]. The
18 intact proteins were identified as a stable panel of urinary
proteins typical of a healthy population.
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Figure 5. Gene Ontology (GO) term comparison between MAPU urinary proteome database and our urinary proteome
database. All results were created using the ClueGO v. 1.2 software. Evidence codes used GO_Biological_Process_12.10.2009,
GO_Cellular_Component_12.10.2009, and GO_Molecular_Function_12.10.2009. (A) Terms specific for MAPU urinary proteome database:
43. (B) Terms specific for our urinary proteome database: 9. (C) Terms common to both MAPU and our urinary proteome databases (A
high-resolution version of this figure can be found in the Supporting Information).
3.4 Validation of the 18 common urinary intact
proteins by ELISA
To determine the fluctuation levels of these 18 proteins in
healthy individuals, we further performed ELISA assays on
the urine samples from eight healthy donors (four males
and four females) taken five times over 2 months (i.e. once
every 2 weeks). The fluctuations of the concentration levels
of COL6A1, GC, RBP4, DNAse1, GAA, SERPING1, CTSD,
KNG1, UMOD, PIGR, AHSG, A1BG, AMBP, AZGP1, PT-
GDS, HPX, CD14, and ORM1 proteins in urine samples are
reported in Table 5. The individual CV values for these 18
proteins ranged between 0.088 and 0.91 and the interday vari-
ations were the major individual sources of variation (Fig. 6).
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Table 2. The common abundant urinary proteins identified in a human healthy population
Accession_number Protein MW Protein pI Entry_name
IPI00022895 54 272.8 5.58 A1BG alpha-1B-glycoprotein precursor
IPI00021440 41 793.1 5.31 ACTG1 actin, cytoplasmic 2
IPI00022431 39 324.9 5.43 AHSG alpha-2-HS-glycoprotein precursor
IPI00022426 38 999.7 5.95 AMBP protein precursor
IPI00025476 57 707.2 6.6 AMY1B
IPI00221224 109 540.1 5.31 ANPEP aminopeptidase N
IPI00298828 38 298.4 8.34 APOH beta-2-glycoprotein 1 precursor
IPI00166729 34 258.9 5.71 AZGP1 alpha-2-glycoprotein 1, zinc
IPI00004101 44 998.7 6.58 BHMT betaine-homocysteine S-methyltransferase 1
IPI00744685 65 050.9 6.21 BTD uncharacterized protein BTD (fragment)
IPI00783987 187 149.1 6.02 C3 complement C3 precursor (fragment)
IPI00654875 192 794.5 6.74 C4B complement C4-B precursor
IPI00176427 42 785.5 5.92 CADM4 cell adhesion molecule 4 precursor
IPI00029260 40 076.4 5.84 CD14 monocyte differentiation antigen CD14 precursor
IPI00002435 29 156.6 8.03 CD27 antigen precursor
IPI00305064 81 554 5.13 CD44 isoform CD44 of CD44 antigen precursor
IPI00099670 79 667.4 5.13 CEL carboxyl ester lipase precursor
IPI00400826 57 832.9 6.25 CLU clusterin isoform 1
IPI00329573 333 148.3 5.38 COL12A1 isoform 1 of collagen alpha-1(XII) chain precursor
IPI00291136 108 529.9 5.26 COL6A1 collagen alpha-1(VI) chain precursor
IPI00017601 122 205.8 5.44 CP ceruloplasmin precursor
IPI00556665 55 607 6.57 CSF1 colony stimulating factor 1 isoform a variant (fragment)
IPI00019954 16 511.2 8.32 CST6 cystatin-M precursor
IPI00011229 44 552.5 6.1 CTSD cathepsin D precursor
IPI00889603 398 738.6 5.13 CUBN cubilin
IPI00031065 31 433.9 4.71 DNASE1 deoxyribonuclease-1 precursor
IPI00025846 99 962.2 5.18 DSC2 isoform 2 A of desmocollin-2 precursor
IPI00000073 133 947.1 5.55 EGF pro-epidermal growth factor precursor
IPI00019568 70 037.3 5.64 F2 prothrombin precursor (fragment)
IPI00073772 36 814.7 6.54 FBP1 fructose-1,6-bisphosphatase 1
IPI00640044 32 690.7 8.36 FCGR3 A Fc fragment of IgG, low-affinity IIIa, receptor for
IPI00883772 105 324.4 5.62 GAA acid alpha-glucosidase preproprotein
IPI00555812 52 964 5.4 GC vitamin D-binding protein precursor
IPI00441344 76 091.3 6.1 GLB1 isoform 1 of beta-galactosidase precursor
IPI00012102 62 082.5 8.6 GNS N-acetylglucosamine-6-sulfatase precursor
IPI00102300 67 309.3 9.11 GP6 isoform 3 of platelet glycoprotein VI precursor
IPI00045512 613 707.5 6.04 HMCN1 hemicentin 1
IPI00022488 51 676.7 6.55 HPX hemopexin precursor
IPI00024284 468 827.8 6.06 HSPG2 basement membrane-specific heparan sulfate proteoglycan core protein
precursor
IPI00016915 29 130.5 8.25 IGFBP7 insulin-like growth factor-binding protein 7 precursor
IPI00829944 51 254.2 7.88 IGHG1 IGHG1 protein
IPI00294193 103 325.9 6.51 ITIH4 isoform 1 of interalpha-trypsin inhibitor heavy chain H4 precursor
IPI00304808 28 889.7 4.62 KLK1 kallikrein-1 precursor
IPI00797833 47 901.5 6.29 KNG1 kininogen 1
IPI00743064 22 902.5 9.02 LCN2 uncharacterized protein LCN2
IPI00023673 65 331.4 5.13 LGALS3BP galectin-3-binding protein precursor
IPI00024292 521 961.3 4.89 LRP2 low-density lipoprotein receptor-related protein 2 precursor
IPI00294713 75 733.9 5.47 MASP2 isoform 1 of Mannan-binding lectin serine protease 2 precursor
IPI00015525 104 417 5.5 MMRN2 multimerin-2 precursor
IPI00008787 82 167 6.1 NAGLU alpha-N-acetylglucosaminidase precursor
IPI00009901 14 478.6 5.1 NUTF2 nuclear transport factor 2
IPI00884926 23 539.7 5.02 ORM1 orosomucoid 1 precursor
IPI00021085 21 730.9 8.92 PGLYRP1 peptidoglycan recognition protein precursor
IPI00004573 83 284 5.59 PIGR polymeric immunoglobulin receptor precursor
IPI00009276 30 715.3 8.8 PROCR endothelial protein C receptor precursor
IPI00012540 97 202.6 6.97 PROM1 prominin-1 precursor
IPI00219825 61 693.2 5.12 PSAP prosaposin
IPI00013179 21 028.9 7.65 PTGDS prostaglandin-H2 D-isomerase precursor
IPI00022420 23 010.1 5.76 RBP4 plasma retinol-binding protein precursor
IPI00009027 18 731.1 5.65 REG1 A lithostathine 1 alpha precursor
IPI00014048 17 644.4 9.1 RNASE1 ribonuclease pancreatic precursor
IPI00019449 18 354.3 9.1 RNASE2 nonsecretory ribonuclease precursor
IPI00007047 10 834.6 6.51 S100A8 protein S100-A8
IPI00027462 13 242.1 5.71 S100A9 protein S100-A9
IPI00170635 27 039.2 7 SECTM1 secreted and transmembrane protein 1 precursor
IPI00007221 45 702 9.3 SERPINA5 plasma serine protease inhibitor precursor
IPI00291866 55 154.5 6.09 SERPING1 plasma protease C1 inhibitor precursor
IPI00021000 35 422.9 4.37 SPP1 isoform A of osteopontin precursor
IPI00793330 12 252.2 5.85 UBC
IPI00640271 73 571.5 5.08 UMOD 74 kDa protein
IPI00291488 12 993.1 4.69 WFDC2 isoform 1 of WAP four-disulfide core domain protein 2 precursor
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2012, 12, 1059–1072 1067
Figure 6. ELISA scatter plots of 18 urinary protein levels for five time points during 2 months observed in eight healthy donors (four males
and four females). A total of 40 urinary protein samples, which were collected five times over 2 months from four male and four female
healthy donors, were assayed for the plotted proteins. All values are adjusted for total protein levels. The horizontal axis legend represents:
M, male; F, female.
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Table 3. Characterization of a panel of 18 intact common urinary proteins
IPI ID Official symbol Localization Genetic disease Glycosylation
IPI00291136 COL6A1 Extracellular (GO:0005576) Bethlem myopathy Null
IPI00742696 GC Extracellular (GO:0005576) GC1/GC2 polymorphism Null
IPI00022420 RBP4 Extracellular (GO:0005576) Retinol-binding protein deficiency Null
IPI00031065 DNASE1 Extracellular (GO:0005576) Systemic lupus erythematosus, susceptibility
to
Null
IPI00293088 GAA Lysosome (GO:0005764) Acid alpha-glucosidase, allele 4 Glycosylation
IPI00291866 SERPING1 Extracellular (GO:0005576) Angioedema, hereditary, autosomal recessive Glycosylation
IPI00011229 CTSD Extracellular (GO:0005576) Ceroid lipofuscinosis, neuronal, 10 Glycosylation
IPI00797833 KNG1 Extracellular (GO:0005576) Fitzgerald trait Glycosylation
IPI00640271 UMOD Extracellular (GO:0005576) Glomerulocystic kidney disease with
hyperuricemia and isosthenuria
Glycosylation
IPI00004573 PIGR Extracellular (GO:0005576) IgA nephropathy, susceptibility to Glycosylation
IPI00022431 AHSG Extracellular (GO:0005576) Leanness, susceptibility to Glycosylation
IPI00022895 A1BG Extracellular (GO:0005576) Null Glycosylation
IPI00022426 AMBP Extracellular (GO:0005576) Null Glycosylation
IPI00166729 AZGP1 Extracellular (GO:0005576) Null Glycosylation
IPI00013179 PTGDS Extracellular (GO:0005576) Null Glycosylation
IPI00022488 HPX Extracellular (GO:0005576) Null Glycosylation
IPI00029260 CD14 Extracellular (GO:0005576) Null Glycosylation
IPI00884926 ORM1 Extracellular (GO:0005576) Orosomucoid polymorphism Glycosylation
Table 4. The relationship between a panel of 18 common urinary proteins and diseases
ORM1a,b) Acute kidney injury after cardiac surgery in children [44]. Diabetic nephropathy [9]. Interstitial
cystitis/painful bladder syndrome [45].
AHSGa,b) Acute kidney injury [6,7]. Vascular calcifications [46,47]. Breast cancer [48].
AMBPa,b) IgA nephropathy[49]. Acute hepatitis E [50]. Acute kidney injury after cardiac surgery in children [44].
Renal toxicity in trichloroethylene-exposed persons [51]. Diabetes mellitus type 2 [30].
AZGP1a,b) Diabetes mellitus type 2 [30]. Cancer cachexia [31]. Acute kidney injury after cardiopulmonary bypass
surgery [32]. Acute rejection after renal transplantation [5].
CTSDa,b) Renal cell carcinoma [3]. Colon adenocarcinoma [52].
CD14a,b) Polycystic kidney disease [53]. Benign prostatic hyperplasia [54].
HPXa,b) Interstitial cystitis/painful bladder syndrome [45]. Childhood HIV-associated renal diseases [55].
KNG1a,b) Ovarian carcinoma [56]. Kidney chronic allograft dysfunction [26].
SERPING1a,b) Acute kidney rejection [4].
PTGDS Early gentamicin-induced renal damage [57]. Lupus nephritis [58]. Vascular injury in type 2 diabetes
patients [59].
UMODa) IgA nephropathy [25]. Kidney chronic allograft dysfunction [26]. Autosomal dominant polycystic kidney
disease [27]. Acute kidney rejection [4]. Kidney stone disease [28,29].
GCb) Multiple myeloma [60]. Neuromyelitis optica [61]. Acute renal allograft rejection [33]. Multiple sclerosis
[62].
RBP4a,b) Diabetes mellitus type 2 [30]. Diabetic nephropathy [63]. Childhood HIV-associated renal diseases [55].
A1BGa,b) Pediatric steroid-resistant nephrotic syndrome [64].
PIGRa,b)
DNASE1
COL6A1a)
GAAa)
a) Urinary exosome;
b) Plasma
3.5 Characterization of the stable set of urinary
proteins
To learn the characteristics of these 18 urinary proteins, we
firstly analyzed them using the HPRD database, which is a
most reliable database. The typical features of such proteins,
including information aboutHPRDID, official symbol, glyco-
sylation, and genetics disease, are reported in Table 3. Almost
all of them are extracellular proteins, save the plasma protein
GAA, and 14 of them (77.8%) can be modified via glycosyla-
tion. According to the HPRD database, 12 of 18 proteins are
associatedwith genetic ailments. To further learn the relation-
ships between these 18 proteins and diseases, we searched the
Pub Med database and found that 14 proteins, that is exclud-
ing DNAse1, PIGR, GAA, and COL6A1, had been reported
as potential disease biomarkers (Table 4). After comparing
the same 18 proteins with the plasma proteome and the uri-
nary exosomal proteome reported by Pisitkun et al. [23] and
Gonzales et al. [24], we found that ten urinary proteins (i.e.
A1BG, AHSG, AMBP, AZGP1, CD14, CTSD, HPX, KNG1,
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ORM1, PIGR, RBP4, and SERPING1) were presented in both
plasma and urinary exosome proteomes, three urinary pro-
teins (i.e. COL6A1,GAA, andUMOD) in the urinary exosome
proteome, one urinary protein (GC) in the plasma proteome,
and two urinary proteins (DNAse1 and PTGDS) only in urine
(Table 4).
4 Discussion
4.1 The urinary proteome database of a human
healthy population
In this study, the urinary proteome of a human healthy pop-
ulation was analyzed by means of four fractionation tech-
niques (i.e. in-gel, 2D-LC, OFFGEL, and mRP) coupled with
HPLC-Chip-MS/MS. The overall features of the datasets de-
rived from the four fractionation techniques are shown in
Fig. S3, and similar trends were observed among these four
datasets concerning the distributions of Mr’s, pI, and pre-
dicted cellular localizations (Supporting Information Fig. S3).
This demonstrated that the intrinsic bias linked to protein
identification inherent to each separation method could be
minimized through the parallel use of multiple fractiona-
tion techniques. Among the four separation methods, the
OFFGEL approach identified the largest number of pro-
teins while also providing quantitative information, but re-
quired much more work and time; the in-gel approach iden-
tified the second largest number of proteins along with Mr’s
information, but was not suitable for appraising protein
abundance.
A total of 1641 urinary proteins were identified with a high
confidence (Supporting Information Data S1). Through com-
paring them with MAPUs data, we observed approximately
50% of protein overlap (Fig. 4 and Supporting Information
Data S2) and 95% of similarity with GO functional categories
(Fig. 5). Alike results obtained by further comparisons with
four other urinary proteomes (data not shown). This made
us confident that the data we report in this study are reliable.
Due to the considerable degree of dynamic variations in the
urinary proteome, it was required to further establish the ex-
istence of a stable set of urinary proteins in a human healthy
population by controlling such urinary proteome changes
[15].
4.2 A stable panel of urinary proteins in a human
healthy population
The urinary proteome differs from one to another individ-
ual and according to the actual age [15]. In this study, the
age-related variations were reduced by limiting urine sam-
ple collection to healthy donors with an age range of 18–22
years, while the interindividual variations were adequately
controlled by using urine samples from a total of 200 persons
(Fig. 1). The urinary proteome also differs between sexes
[15]. Thus, urinary proteomes derived from 100male and 100
female healthy donors were determined, and 619 (37.7%)
proteins were found in both datasets. And there was no sig-
nificant difference between male and female datasets in the
distribution of Mr’s, pI, and the predicted cellular localiza-
tions (Supporting Information Fig. S2). Furthermore, a total
of 14 male-predominant and eight female-predominant sta-
ble urinary proteins (Supporting Information Data S11) were
identified by comparing themale and female datasets. Among
the 14 male-predominant proteins, KLK3 was confirmed to
be a male-specific protein.
Since the urinary proteome changes markedly over time
[15], a stable set of urinary proteins proper of a human healthy
population should obtain from urine samples with low in-
terday and intergender variations. Seventy abundant proteins
were identified by us as potential candidates for a stable panel
of urinary proteins typical of a healthy population with inter-
day and intergender variations within 0.25 (Supporting Infor-
mation Data S5, S8, S9). Finally, among the just mentioned
70 proteins, 56 were further confirmed to belong to a stable
set of urinary proteins via comparisons with the previously
published five largest urinary proteomes [10–14] (Table 2).
Since protein fragments in urine could be incorrectly iden-
tified as intact proteins by peptide identification based on
MS/MS proteomics, some of the proteins in this groupmight
have derived from the wrong identification of protein frag-
ments. Therefore, we employed a 10 kDa cut-off ultrafiltration
membrane to remove the low molecular weight polypeptides
from the urine samples. Next, the 18 intact proteins were
confirmed as constituting a stable urinary panel proper of
a healthy population by comparisons with the urinary pro-
teomes from in-gel datasets [10] and 2DE datasets [18, 19].
Finally, all of the 18 urinary proteins were validated with
ELISA assays in samples taken from eight healthy individu-
als during 2 months. The individual CV values for these 18
proteins ranged between 0.088 and 0.91 (Table 5). Among
them, the CV values for GC, AHSG, GAA, AZGP, UMOD,
and AMBP were lower than 0.25. We surmise that these 18
urinary proteins represent a stable set proper of a healthy
population.
4.3 A panel comprising 18 intact urinary proteins
reflects the human good health condition
According to the HPRD database, 12 of the 18 common uri-
nary proteins were linked to genetic diseases (Table 3). It is
interesting to find that 14 of the 18 common urinary proteins
were previously indicated as potential disease biomarkers
(Table 4). Each of these 14 proteins was reported as a potential
biomarker for multiple diseases rather than for a single dis-
ease (Table 4). For example, UMOD turned up to be a likely
biomarker for IgA nephropathy [25], kidney chronic allograft
dysfunction [26], autosomal dominant polycystic kidney dis-
ease [27], acute kidney rejection [4], and kidney stone disease
[28,29]. Another example was AZGP1, which was found to be
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Table 5. The fluctuation levels of the 18 common proteins in a
healthy individual’s urine
Official Protein concentration CV
symbol (ng/mg total protein)
mean ± SD (n = 40)
GC 149.70 ± 13.23 0.088
AHSG 5327.55 ± 568.21 0.107
GAA 126.10 ± 17.54 0.139
AZGP 15.70 ± 2.24 0.143
UMOD 925.86 ± 198.44 0.214
AMBP 2431.20 ± 572.60 0.236
PIGR 753.93 ± 245.44 0.326
A1BG 56.34 ± 23.74 0.421
COL6A1 31.16 ± 13.39 0.430
Dnase1 0.47 ± 0.23 0.490
CTSD 58.07 ± 28.75 0.495
RBP4 30.71 ± 15.54 0.506
CD14 24.56 ± 13.01 0.530
KNG1 370.17 ± 224.38 0.606
HPX 18.65 ± 11.48 0.615
PTGDS 22.91 ± 14.27 0.623
SERPING1 217.50 ± 163.02 0.749
ORM1 21.90 ± 19.92 0.910
a probable biomarker for diabetes mellitus type 2 [30], can-
cer cachexia [31], acute kidney injury after cardiopulmonary
bypass surgery [32], and acute rejection after renal transplan-
tation [5]. In addition, several of these proteins were indicated
as prospective biomarkers for the same illness (Table 4). For
example, AMBP, AZGP1, andRBP4were reported to be likely
biomarkers for diabetes mellitus type 2 [30]. Other examples
are AZGP1 [5], SERPING1 [4], UMOD [4], and GC [33], which
were reported as potential biomarkers for acute rejection after
kidney transplantation. These lines of evidence indicate that
the 18 common urinary proteins could, in the first instance,
serve as potential biomarkers reflecting the human healthy
status rather than certain diseases. It may be reasonable to
assume that, as a group, these 18 proteins could indicate
a human healthy condition. Abnormalities in this common
urinary protein panelmay awaken people’s attention to an un-
healthy condition. On the other hand, the rescue of a normal
common urinary protein panel may indicate that a patient is
healing. However, further assessments of the normal fluctu-
ations of each single urinary protein pertaining to the panel
are needed prior to any translation to clinical practice. Subse-
quently, intensive clinical studies would also be required to
determine the ranges within which the dynamic changes in
the protein panel still indicate a human healthy condition.
It is known that glycosylation changes on glycoproteins
are closely associated with diseases. Notably, 14 of the 18
common urinary proteins are glycoproteins (Table 3), and 12
were reported as posttranslationally modified proteins [19].
Glycosylation changes of these proteins in the serum might
contribute to diseases [34–43] (Supporting Information Table
S3). Furthermore, we observed that IGHG1 protein had the
same glycosylation modification in both urine and serum
(data not shown). Hence, it is needed to further investigate
whether glycosylative changes in these 14 common urinary
glycoproteins might reveal a diseased status of the urinary
system.
4.4 Concluding remarks
Our present study has allowed to identify with a high confi-
dence not only a human urinary proteome comprising 1641
proteins, but even a reproducible panel of 18 intact pro-
teins, which pertains to a human healthy population. This
latter panel could serve as a potential biomarker indicative of
healthy conditions.
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